Venkateshwar Polsani, MD
Cardiovascular Disease · Atlanta, GANPI 1720035835
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (40.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 57.0% of the total. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $239.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$28K
- Heartflow, Inc.$19K
- Novartis$513
- Amgen$263
- Artrya Ltd.$179
- Abiomed$146
- plus $818 from 17 others
Across 25 payments — averaging $8451.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$100K
- Cleerly, Inc.$78K
- Siemens Medical Solutions USA, Inc.$33K
What the payments were for
- Consulting fees$3,9438%
- Speaking & faculty fees$17,61436%
- Travel & lodging$19,76240%
- Food & beverage$7,55615%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 92 | $27,876 |
| Heartflow, Inc. | 38 | $19,099 |
| Novartis | 30 | $513 |
| Amgen | 8 | $263 |
| Artrya Ltd. | 2 | $179 |
| Abiomed | 1 | $146 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $131 |
| E.r. Squibb & Sons, L.L.C. | 6 | $112 |
| GE HealthCare | 3 | $109 |
| Scpharmaceuticals Inc. | 5 | $85 |
| Canon Medical Systems USA, Inc. | 1 | $68 |
| Angiodynamics, Inc. | 2 | $49 |
| Edwards Lifesciences | 1 | $44 |
| Amarin Pharma, Inc. | 2 | $39 |
| Pfizer | 1 | $37 |
| Boston Scientific | 2 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Merck | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Abbott | 1 | $15 |
| AbbVie | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$18,447
- SOMATOM Force$8,048
- ACUSON SC2000 Diagnostic Ultrasound System$3,560
- MAGNETOM Sola$2,387
- System SOMATOM Drive$1,000
- ACUSON Origin Diagnostic Ultrasound System$972
- NAEOTOM Alpha$841
- MAGNETOM Free.Max$452
- syngo.via$421
- ACUSON Sequoia Diagnostic Ultrasound System$271
- MAGNETOM Aera$200
- Impella$146
- MAGNETOM Vida$141
- Repatha$135
- Biograph Vision 600 (8 Ring/64 CT)$130
- LifeVest$107
How this compares
$48,894 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 45 | $51,897 |
| EntrestoSacubitril/Valsartan | 35 | $34,870 |
| JardianceEmpagliflozin | 20 | $22,596 |
| Rosuvastatin Calcium | 64 | $1,079 |
| Metoprolol Succinate | 62 | $978 |
| Atorvastatin Calcium | 113 | $791 |
| Valsartan | 21 | $573 |
| Losartan Potassium | 56 | $495 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $380 |
| Ezetimibe | 14 | $346 |
| Spironolactone | 43 | $246 |
| ClopidogrelClopidogrel Bisulfate | 20 | $233 |
| Amlodipine Besylate | 45 | $183 |
| Carvedilol | 23 | $183 |
| Nitroglycerin | 12 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $37 | $51,89745 claims |
| NovartisEntresto | $513 | $34,87035 claims |
| Boehringer IngelheimJardiance | $19 | $22,59620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Atlanta
- Joseph MillerAtlanta$573K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Mani VannanAtlanta$157K
- Victor CorriganAtlanta$114K
- Elizabeth OfiliAtlanta$107K
- Isida BykuAtlanta$78K
- Cindy GrinesAtlanta$75K
- Anekwe OnwuanyiAtlanta$56K
- Melvin EcholsAtlanta$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.